O’Brien and colleagues’ model speculated that in patients with early-stage NSCLC, TEM cells encountered antigens during tumor formation and were converted to CD103+TRM cells that exerted anti-tumor activity (75). The gene discussed is ITGAE; the disease is non-small cell lung carcinoma.